A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

Inclusion Criteria: * Curative surgery for carcinoma performed at least three months prior to treatment start * Age ≥18 years * ECOG Performance status (PS): 0 * Life expectancy: at least 3 months * Laboratory requirements: * White Blood Count (WBC) ≥ 3 x 109/L * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelet count ≥ 100 x 109/L * Haemoglobin ≥ 10.0 g/dL * Total bilirubin level ≤ 1.5 ULN * AST and ALT ≤ 2.5 x ULN * Creatinine ≥ 1.5 ULN * Albumin \> 30 g/L * No expectation of anti-cancer therapy or immunotherapy during the trial period, hormone therapy given as adjunctive or contraceptive therapy is permitted * Must be willing to practice acceptable barrier methods of birth control to prevent pregnancy * The patient is willing and able to comply with the protocol and agrees to return to the hospital for follow-up visits and examination * The patient has been fully informed about the study and has signed the informed consent form Exclusion Criteria: * Has received an investigational drug within 4 weeks prior to study drug administration, or is scheduled to receive one during the treatment or the post-treatment period * Has received immunotherapy or been vaccinated within 12 weeks prior to study drug administration or has not recovered from adverse events due to such agents * Has received external radiotherapy or cytotoxic chemotherapy within the last 4 weeks prior to study drug administration, or has not recovered from adverse events (\< Grade 1) due to agents administered more than 4 weeks earlier * Has received imiquimod within 12 weeks prior to study drug administration or has not recovered from associated adverse events * Is currently on any agent with a known effect on the immune system * Has any other serious illness or medical condition such as but not limited to: * Any uncontrolled infection or infection requiring antibiotics * Uncontrolled cardiac failure Classification III or IV (New York Heart Association) * Uncontrolled systemic and gastro-intestinal inflammatory conditions * Bone marrow dysplasia * History of auto-immune disease * History of adverse reaction to vaccines * Known history of positive tests for HIV/AIDS, hepatitis B or C * Is pregnant or breastfeeding